GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT01831804
- Locations
- πΊπΈ
GSK Investigational Site, Dallas, Texas, United States
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT01831791
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
- Conditions
- Dentinal Hypersensitivity
- Interventions
- Drug: Sodium monofluorophosphate dentifriceDrug: Sodium Fluoride dentifrice
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT01831817
- Locations
- πΊπΈ
Salus Research, Inc., Fort Wayne, Indiana, United States
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster vaccine (GSK1437173A)
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 96
- Registration Number
- NCT01827839
- Locations
- π·πΊ
GSK Investigational Site, Ekaterinburg, Russian Federation
Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects
- Conditions
- Crohn's Disease
- Interventions
- Drug: GSK1605786 capsule
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT01827631
- Locations
- π¨π³
GSK Investigational Site, Shanghai, China
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
- Conditions
- Hepatitis C
- Interventions
- Drug: GSK2336805
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT01827657
- Locations
- πΊπΈ
GSK Investigational Site, Knoxville, Tennessee, United States
Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity
- Conditions
- Dentine Hypersensitivity
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 119
- Registration Number
- NCT01827670
- Locations
- πΊπΈ
Salus Research, Inc., Fort Wayne, Indiana, United States
Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT01827644
- Locations
- π¦πΊ
GSK Investigational Site, Melbourne, Victoria, Australia
Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics
- Conditions
- Gastrointestinal Mucosal Damage
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01822665
- Locations
- πΊπΈ
Houston Institute for Clinical Research, Houston, Texas, United States
A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT01822639
- Locations
- π¦πΊ
GSK Investigational Site, Randwick, New South Wales, Australia